AstraZeneca says lung cancer drug trial shows no significant improvement
- 10-Sep-2024
Detailed results from one of AstraZeneca’s (AZN.L), opens new tab key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial. The overall survival, or OS rates, in the TROPION-Lung01 trial “did not reach statistical significance”, the company said in a […]
AstraZeneca to build $1.5 bln cancer drug facility in Singapore
- 20-May-2024
SINGAPORE: British pharmaceutical giant AstraZeneca said Monday that it planned to build a $1.5 billion plant in Singapore to manufacture next-generation drugs to treat cancer. The facility, to be ready by 2029, will produce antibody-drug conjugates (ADCs), a promising type of treatment that attacks cancer cells without damaging the surrounding healthy ones, the company said […]
AstraZeneca says it will withdraw COVID-19 vaccine globally
- 08-May-2024
AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a “surplus of available updated vaccines” since the pandemic. The company also said it would proceed to withdraw the vaccine Vaxzevria’s marketing authorizations within Europe. “As multiple, variant COVID-19 vaccines have since been developed there is a surplus of […]
AstraZeneca’s Imfinzi shows promise in treating aggressive lung cancer
- 05-Apr-2024
AstraZeneca (AZN.L), opens new tab said on Friday its blockbuster cancer drug Imfinzi helped improve overall and progression-free survival in patients with limited-stage small cell lung cancer. The drug demonstrated “statistically significant and clinically meaningful improvement” in the dual primary goals of overall survival and progression-free survival in patients for whom the disease had not […]
AstraZeneca bets on next-generation cancer therapy
- 19-Mar-2024
AstraZeneca said on Tuesday it will buy Canadian drug developer Fusion Pharmaceuticals, for $2 billion in cash as the Anglo-Swedish drugmaker bets on next-generation cancer treatments. The deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when data from Novartis’ treatment showed that the drug extended […]
AstraZeneca returns to profit on higher drugs revenue
- 10-Nov-2022
LONDON: British pharmaceuticals giant AstraZeneca on Thursday announced a return to third-quarter profit on increased revenue from sales of its drugs. Net profit for the Covid-vaccine maker came in at $1.64 billion in the July-September period, a statement said. That compared with a loss after tax of $1.65 billion in the third quarter of last […]
Lynparza: AstraZeneca gets EU backing for breast cancer therapies
- 28-Jun-2022
AstraZeneca said on Monday two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company’s oncology portfolio. Lynparza, a cancer drug developed jointly with US-based Merck, was backed for standalone use or in combination with endocrine therapy in adults […]
Pakistan approves another Covid-19 vaccine for booster shots
- 19-Jan-2022
ISLAMABAD: With the positivity rate of coronavirus currently hovering at 9.48 per cent, the federal health ministry on Wednesday included another vaccine in the Covid-19 booster set and approved the use of AstraZeneca’s booster shot for general public, ARY News reported. The move comes to facilitate citizens waiting to get Covid booster shots of their […]
Rare spinal condition listed as side effect of AstraZeneca’s COVID-19 vaccine
- 14-Jan-2022
A safety panel of the European drug regulator on Friday recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca’s COVID-19 vaccine. The vaccine has faced several setbacks, including production delays and probes by regulators following rare cases of severe side effects such as blood clots with low platelets, which […]
AstraZeneca says third dose helps against Omicron
- 13-Jan-2022
AstraZeneca said on Thursday that preliminary data from a trial showed that its COVID-19 shot, Vaxzevria, generated an increase in antibodies against the Omicron and other variants when given as a third booster dose. The increased response, also against the Delta variant, was seen in a blood analysis of people who were previously vaccinated with […]